

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.

Petitioner

v.

HORIZON THERAPEUTICS, INC.

Patent Owner

Case IPR2015-01117 (Patent 8,642,012)

**PETITIONER PAR PHARMACEUTICAL, INC.'S UPDATED MANDATORY
NOTICES PURSUANT TO 37 C.F.R. § 42.8(a)(3)**

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
PO Box 1450
Alexandria, Virginia 22313-1450

Petitioner Par Pharmaceutical, Inc. (“Par”) is a real-party-in-interest for this proceeding. Out of an abundance of caution, and as a result of ongoing integration and reorganization activities, Petitioner identifies the following additional entities as real-parties-in-interest who, going forward, may have control over this proceeding: Endo International PLC; Endo DAC; Endo Management Limited; Endo Luxembourg Holding Company S.a.r.l.; Endo Luxembourg Finance Company I S.a.r.l.; Endo U.S. Inc.; Endo US Holdings Luxembourg I S.a.r.l.; Endo US Holdings Luxembourg II S.a.r.l.; Endo Health Solutions Inc.; Hawk Acquisition Ireland Limited; and Par Pharmaceutical Companies, Inc.¹

¹ Patent Owner Horizon Therapeutics, Inc. (f/k/a Hyperion Therapeutics, Inc.) has asserted that Par Pharmaceutical Companies, Inc. was improperly not named as a real-party-in-interest in its Preliminary Response (Paper 8). As a result of Endo International PLC's acquisition of Par Pharmaceutical, Inc., Petitioner notes that Sky Growth Intermediate Holdings Corporation I, Sky Growth Intermediate Holdings Corporation II, and Par Pharmaceutical Companies, Inc. were merged into and reorganized with Par Pharmaceutical Holdings, Inc., which was immediately thereafter re-named Par Pharmaceutical Companies, Inc. For clarity, the newly reorganized Par Pharmaceutical Companies, Inc. is not identical to the entity previously known by the same name.

IPR2015-01117 (Patent 8,642,012)
Petitioner's Updated Mandatory Notices

Date: October 21, 2015

Respectfully submitted by
K&L Gates LLP,

michael.freno@klgates.com (email)
206.370.7947 (phone)
206.623.7022 (fax)
925 Fourth Avenue, Suite 2900
Seattle, WA 98104

By: Michael J. Freno
Michael J. Freno
Reg. No. 57,163
Customer No. 24573
Lead Attorney for Petitioner

IPR2015-01117 (Patent 8,642,012)
Petitioner's Updated Mandatory Notices

Certification of Service Under 37 C.F.R. § 42.6(e)(4)

A copy of Petitioner Par Pharmaceutical, Inc.'s Updated Mandatory Notices has been served upon the following counsel for the Patent Owner via electronic mail, as agreed to by counsel, on this twenty-first day of October 2015:

Lauren Stevens: lstevens@globalpatentgroup.com

Matthew C. Phillips: matthew.phillips@renaissanceiplaw.com

Dennis Bennett: dennisbennett@globalpatentgroup.com

By: /Michael J. Freno/
Michael J. Freno
Reg. No. 57,163
Customer No. 24573
Date: October 21, 2015
michael.freno@klgates.com (email)
206.370.7947 (phone)
206.623.7022 (fax)
K&L Gates LLP
925 Fourth Avenue, Suite 2900
Seattle, WA 98104